相关实验视频
Updated: Jun 16, 2025

08:05
Assaying Protein Kinase Activity with Radiolabeled ATP
Published on: May 26, 2017
18.3K
双作用激酶抑制剂 影响p38α MAP激酶脱化
Emily J Stadnicki1,2, Hannes Ludewig1,3, Ramasamy P Kumar1,4
1Department of Biochemistry, Brandeis University.
bioRxiv : the preprint server for biology
|August 16, 2024
概括
新的双作用抑制剂同时阻断激酶活性位点,并增强p38α基因激活蛋白激酶 (MAPK) 脱. 这种双重作用揭示了酸酶的结构偏好,指导了改进的治疗性激酶抑制剂设计.
科学领域:
- 生物化学和分子生物学
- 药物发现和开发 药物发现和开发
背景情况:
- 蛋白质酸化调节关键细胞功能,并与各种疾病有关.
- 酶和酸酶是关键的药物标,一些抑制剂显示临床成功.
- 激活环酸化通常会激活激酶,而酸酶会通过脱酸化使它们失活.
研究的目的:
- 为了研究激活循环构成在酶脱化中的作用.
- 为了识别调节p38α基因激活蛋白激酶 (MAPK) 激活循环构造和脱酸化的新型抑制剂.
主要方法:
- 使用现有的激酶抑制剂调节人类p38α MAPK激活环形状.
- 测试开发以测量PPM血清/三联酸酶WIP1.1的脱化率.
- 用X射线晶体学来确定受抑制剂结合和不结合的p38α结构的结构基础.
主要成果:
- 确定了三种抑制剂,这些抑制剂可以通过WIP1.1.增加p38α激活循环的-氨酸脱化速率.
- 这些化合物作为双作用抑制剂,阻断激酶活性部位并刺激脱化.
- X射线结构显示,双作用抑制剂稳定了反转激活环形状,使三因可用于WIP1.1.
结论:
- 激酶激活循环的形状显著影响了酸酶的可访问性和脱化率.
- 酸酶表现出对其酸化位的结构偏好.
- 这项研究提出了一种新的策略,用于设计强效和特定的双作用激酶抑制剂.
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Amplifying Signals via Enzymatic Cascade
8.4K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.4K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

